drugset
drugset / Trial / NCT03139500

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-61803534 and to Evaluate the Effect of JNJ-61803534 on the Pharmacokinetics of Midazolam in Healthy Participants

NCT03139500 ↗

Phase 1 Terminated 47 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindOther

Summary

The purpose of this study is to evaluate the safety and tolerability and pharmacokinetics of JNJ61803534 in healthy participants after administration of single ascending oral doses of JNJ-61803534 (Part 1) and multiple ascending oral doses of JNJ-61803534, administered for 14 consecutive days (Part 2) as well as the potential of JNJ-61803534 to interact with other drugs (Part 3).

Timeline

Start
2017-05-17
Primary completion
2018-04-05
Completion
2018-04-05

Outcome

Outcome not reported

Stopped: “Terminated due to nonclinical findings”

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-61803534 Unknown — Oral
Subject Midazolam Small molecule — Oral

Indications

No indication recorded.